Pablo G. Legorreta
Pablo G. Legorreta's purchase track record
How the stock did after each of Pablo G. Legorreta's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2024 | PROK | $54.74M | -19.9% | -36.7% | +11.4% |
| 6/28/2023 | RPRX | $3.84M | -9.2% | -4.0% | +9.3% |
| 6/12/2023 | RPRX | $2.96M | -10.9% | -11.3% | +6.5% |
| 5/24/2023 | RPRX | $4.84M | -7.3% | -14.4% | +10.7% |
| 5/16/2023 | RPRX | $7.68M | -9.8% | -16.1% | +9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026. ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.
Transaction History
| RPRX | ▲ Buy | Grant | 65,216 | $0 | 8/5/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 143,821 | $0 | 5/6/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 157,828 | $0 | 2/11/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 36,559 | $0 | 11/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 21,901 | $0 | 8/6/2025 | View on chart |
| PROK | ▼ Sell | Other | 3,823,996 | $0 | 6/3/2025 | View on chart |
| PROK | ▼ Sell | Other | 3,823,996 | $0 | 6/3/2025 | View on chart |
| RPRX | ▼ Sell | Other | 530,348 | $0 | 5/16/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 288,352 | $0 | 5/8/2025 | View on chart |
| PROK | ▼ Sell | Other | 532,535 | $0 | 2/4/2025 | View on chart |
| PROK | ▼ Sell | Other | 532,535 | $0 | 2/4/2025 | View on chart |
| PROK | ▲ Buy | Open Market | 22,617,909 | $54.7M | 6/13/2024 | View on chart |
| PROK | ▼ Sell | Other | 748,952 | $0 | 2/5/2024 | View on chart |
| PROK | ▼ Sell | Other | 748,952 | $0 | 2/5/2024 | View on chart |
| RPRX | ▼ Sell | Other | 383,000 | $0 | 11/16/2023 | View on chart |
| PROK | ▼ Sell | Other | 5,289,055 | $0 | 10/30/2023 | View on chart |
| PROK | ▼ Sell | Other | 5,289,055 | $0 | 10/30/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 130,000 | $3.8M | 6/28/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 45,000 | $1.5M | 6/13/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 45,000 | $1.5M | 6/12/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 150,000 | $4.8M | 5/24/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 69,612 | $2.3M | 5/17/2023 | View on chart |
| RPRX | ▲ Buy | Open Market | 160,388 | $5.4M | 5/16/2023 | View on chart |
| RPRX | ▼ Sell | Gift | 292,190 | $0 | 12/30/2022 | View on chart |
| RPRX | ▼ Sell | Other | 462,031 | $0 | 4/14/2022 | View on chart |
| RPRX | ▼ Sell | Other | 350,000 | $0 | 4/14/2022 | View on chart |
| RPRX | ▼ Sell | Other | 428,420 | $0 | 10/20/2020 | View on chart |
| RPRX | ▼ Sell | Other | 493,750 | $0 | 6/16/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.